These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30879981)

  • 1. Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia.
    Weber N; Jackson K; McWhinney B; Ungerer J; Kennedy G; Lipman J; Roberts JA
    J Infect Chemother; 2019 Jul; 25(7):503-508. PubMed ID: 30879981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial.
    Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA
    J Antimicrob Chemother; 2015 Aug; 70(8):2369-75. PubMed ID: 25953805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
    Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
    J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
    Maarbjerg SF; Thorsted A; Friberg LE; Nielsen EI; Wang M; Schrøder H; Albertsen BK
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1585. PubMed ID: 34796702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
    Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
    Thorsted A; Kristoffersson AN; Maarbjerg SF; Schrøder H; Wang M; Brock B; Nielsen EI; Friberg LE
    J Antimicrob Chemother; 2019 Oct; 74(10):2984-2993. PubMed ID: 31273375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
    Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
    Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study.
    Areskog Lejbman I; Torisson G; Resman F; Sjövall F
    Acta Anaesthesiol Scand; 2024 Apr; 68(4):530-537. PubMed ID: 38407447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
    Heil EL; Nicolau DP; Farkas A; Roberts JA; Thom KA
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
    Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
    Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.
    Carrié C; Legeron R; Petit L; Ollivier J; Cottenceau V; d'Houdain N; Boyer P; Lafitte M; Xuereb F; Sztark F; Breilh D; Biais M
    J Crit Care; 2018 Dec; 48():66-71. PubMed ID: 30172963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
    Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
    J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
    Chua NG; Loo L; Hee DKH; Lim TP; Ng TM; Hoo GSR; Soong JL; Ong JCL; Tang SSL; Zhou YP; Lee W; Lee LS; Cove M; Ling LM; Kwa AL
    J Crit Care; 2022 Apr; 68():107-113. PubMed ID: 34999376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Personalised antibiotic therapy in a surgical intensive care unit overview of current knowledge and the results of an observational kinetic study].
    Kaška M; Martinková J; Havel E; Kočí J; Fousková A; Solichová D; Kujovská L; Selke-Krulichová I; Práznovec I; Salavec V
    Rozhl Chir; 2014 Sep; 93(9):456-62. PubMed ID: 25301344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.
    Tannous E; Lipman S; Tonna A; Hector E; Hussein Z; Stein M; Reisfeld S
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482679
    [No Abstract]   [Full Text] [Related]  

  • 20. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.